Ngā hua rapu - David Kavanagh

Whakamahine hua
  1. 1
    Genetics and complement in atypical HUS

    Genetics and complement in atypical HUS mā David Kavanagh, Tim Goodship

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

    Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome mā Edwin Wong, David Kavanagh

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea

    Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea mā Vicky Brocklebank, David Kavanagh

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Diseases of complement dysregulation—an overview

    Diseases of complement dysregulation—an overview mā Edwin Wong, David Kavanagh

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Diagnosis and treatment of thrombotic microangiopathy

    Diagnosis and treatment of thrombotic microangiopathy mā Gemma L. Thompson, David Kavanagh

    I whakaputaina 2022
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Complement therapy in atypical haemolytic uraemic syndrome (aHUS)

    Complement therapy in atypical haemolytic uraemic syndrome (aHUS) mā Edwin Wong, Tim Goodship, David Kavanagh

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Atypical haemolytic uraemic syndrome

    Atypical haemolytic uraemic syndrome mā David Kavanagh, Tim Goodship, Anna Richards

    I whakaputaina 2006
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Atypical Hemolytic Uremic Syndrome, Genetic Basis, and Clinical Manifestations

    Atypical Hemolytic Uremic Syndrome, Genetic Basis, and Clinical Manifestations mā David Kavanagh, Timothy H.J. Goodship

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Atypical Hemolytic Uremic Syndrome

    Atypical Hemolytic Uremic Syndrome mā David Kavanagh, Tim Goodship, Anna Richards

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Peritoneal dialysis-associated peritonitis in Scotland (1999-2002)

    Peritoneal dialysis-associated peritonitis in Scotland (1999-2002) mā David Kavanagh, Gordon Prescott, Robert Mactier

    I whakaputaina 2004
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Thrombotic Microangiopathy and the Kidney

    Thrombotic Microangiopathy and the Kidney mā Vicky Brocklebank, Katrina Wood, David Kavanagh

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Complement and the prothrombotic state

    Complement and the prothrombotic state mā Christoph Q. Schmidt, Hubert Schrezenmeier, David Kavanagh

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Transplantation in Atypical Hemolytic Uremic Syndrome

    Transplantation in Atypical Hemolytic Uremic Syndrome mā David Kavanagh, Anna Richards, Tim Goodship, Hannu Jalanko

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    A national specialized service in England for atypical haemolytic uraemic syndrome—the first year’s experience

    A national specialized service in England for atypical haemolytic uraemic syndrome—the first year’s experience mā Neil Sheerin, David Kavanagh, Timothy H.J. Goodship, Sally Johnson

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Complement factor I: Regulatory nexus, driver of immunopathology, and therapeutic

    Complement factor I: Regulatory nexus, driver of immunopathology, and therapeutic mā Thomas M Hallam, Stephen J. Sharp, Aikaterini Andreadi, David Kavanagh

    I whakaputaina 2023
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Developments in anti-complement therapy; from disease to clinical trial

    Developments in anti-complement therapy; from disease to clinical trial mā Claire L. Harris, Richard B. Pouw, David Kavanagh, Ruyue Sun, Daniel Ricklin

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Advances in understanding of pathogenesis of aHUS and HELLP

    Advances in understanding of pathogenesis of aHUS and HELLP mā Celia J. Fang, Anna Richards, M. Kathryn Liszewski, David Kavanagh, John P. Atkinson

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Disease-associated N-terminal Complement Factor H Mutations Perturb Cofactor and Decay-accelerating Activities

    Disease-associated N-terminal Complement Factor H Mutations Perturb Cofactor and Decay-accelerating Activities mā Isabell Pechtl, David Kavanagh, Nicola McIntosh, Claire L. Harris, Paul N. Barlow

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Structural basis for sialic acid–mediated self-recognition by complement factor H

    Structural basis for sialic acid–mediated self-recognition by complement factor H mā Bärbel S. Blaum, Jonathan P. Hannan, Andrew P. Herbert, David Kavanagh, Dušan Uhrı́n, Thilo Stehle

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Factor B as a therapeutic target for the treatment of complement-mediated diseases

    Factor B as a therapeutic target for the treatment of complement-mediated diseases mā David Kavanagh, Jonathan Barratt, Anna Schubart, Nicholas J.A. Webb, Matthias Meier, Fádi Fakhouri

    I whakaputaina 2025
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: